华纳药厂(688799) - 2025 Q4 - 年度业绩
HWPCHWPC(SH:688799)2026-02-13 07:50

Financial Performance - Total operating revenue for 2025 reached ¥1.5156 billion, an increase of 7.26% compared to ¥1.4129 billion in the previous year[2] - Net profit attributable to shareholders of the parent company was ¥241.47 million, a year-on-year increase of 46.95% from ¥164.32 million[2] - Operating profit rose to ¥245.13 million, reflecting a significant growth of 51.53% compared to ¥161.77 million last year[2] - Basic earnings per share increased to ¥1.84, representing a growth of 47.20% from ¥1.25[2] - The decline in net profit excluding non-recurring gains and losses was 6.01%, with a reported figure of ¥129.95 million compared to ¥138.26 million last year[2] Assets and Equity - Total assets at the end of the reporting period amounted to ¥3.0526 billion, up 24.11% from ¥2.4596 billion at the beginning of the period[2] - Shareholders' equity attributable to the parent company increased to ¥2.0459 billion, a growth of 13.44% from ¥1.8034 billion[2] - The company’s weighted average return on equity improved to 12.77%, an increase of 3.56 percentage points from 9.21%[2] Revenue Drivers - The increase in operating revenue was driven by growth in sales of formulation products, raw materials, and technical service income[6] Capital Changes - The company’s share capital increased by 40.00% due to a capital reserve conversion, raising the number of shares from 93.8 million to 131.32 million[7]

HWPC-华纳药厂(688799) - 2025 Q4 - 年度业绩 - Reportify